Trial Profile
Realisation of established targets for patients with diabetes type 2 at primary care setting.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 22 Sep 2009 Additional lead trial centres identified as reported by Netherlands Trial Register.
- 22 Sep 2009 New source identified and integrated (Netherlands Trial Register record no. NTR391).
- 13 Feb 2006 New trial record.